Neuroendocrine neoplasms (Grade 3 well-differentiated neuroendocrine tumours (NET) or poorly differentiated neuroendocrine carcinomas (NEC)) MedDRA version: 20.0 Level: PT Classification code 10057270 Term: Neuroendocrine carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 21.0 Level: PT Classif
Conditions
Interventions
Trade Name: OPDIVO 10 mg/ml concentrado para solución para perfusión
Product Name: Nivolumab
Product Code: BMS-936558
Pharmaceutical Form: Solution for
Sponsors
Fundación de investigación de HM Hospitales
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients having voluntarily signed and dated an and dated an IRB/IEC-approved written informed consent form in accordance with regulatory and institutional guidelines before the performance of any protocol-related procedures. 2) Patients with advanced/metastatic, histologically confirmed, well-differentiated grade Grade 3 NET or poorly-differentiated NEC of the pancreas, gastrointestinal tract and unknown primary site at diagnosis or after progression to one systemic treatment. Patients will be enrolled in two cohorts based on the therapy of their aforementioned cancer: Cohort 1: Patients with no previous chemotherapy. Cohort 2: Patients who have received one line of chemotherapy. 3) Age > or =18 years. 4) Patients must have measurable disease based on RECIST v.1.1 meeting the following criteria: a) Lesions that have had external beam radiotherapy or loco-regional therapies such as radiofrequency ablation or liver embolization must show evidence of progressive disease based on RECIST v.1.1 to be deemed a target lesion. b) Patients in cohort 2 must show evidence of disease progression by radiologic image techniques according to RECIST v.1.1 within 3 months prior to signing informed consent. 5) Confirmed presence of somatostatin receptors on tumour lesions based on positive PET-Gallium (SomaKit) imaging within 8 weeks prior to enrolment in the study. At least one lesion should have an uptake of 64-Gallium higher than the normal liver according to investigator judgement. 6) Karnofsky Performance Score > or = 60 and Eastern Cooperative Oncology Group (ECOG) performance status (PS) or = 6 months. 8) Adequate normal organ and marrow function as defined below: a) Haemoglobin concentration > or = 8.0 g/dL (5.0 mmol/L). b) WBC > or = 2x109/L (2000/mm3). c) Platelets > or =75x109/L (75x103/mm3). 9) Adequate renal function defined as serum creatinine or = 50 mL/min. 10) Adequate hepatic function defined as total bilirubin or = 3.0 g/dL (or serum albumin or =60 years old and no menses for > or =1 year without an alternative medical cause; OR history of hysterectomy, OR history of bilateral tubal ligation, OR history of bilateral oophorectomy) or must have a negative serum pregnancy test upon study entry. Both women and men must agree to use a medically acceptable method of contraception throughout the treatment period and for six months after discontinuation of treatment. Acceptable methods of contraception include intrauterine device, oral contraceptive, subdermal implant and/or double barrier. 13) Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visit
Exclusion criteria
Exclusion criteria: 1) Lung neuroendocrine tumours, carcinomas or carcinoids. 2) Treatment with >30 mg Octreotide LAR at 3-4 weeks intervals within 12 weeks prior to enrolment in the study. 3) Peptide receptor radionuclide therapy (PRRT) at any time prior to enrolment in the study. 4) Targeted surgery, radiotherapy (external beam), chemotherapy, embolization, interferons, mTOR-inhibitors or other investigational therapy within 12 weeks prior to enrolment in the study. In Cohort 2, chemotherapy should be administered at least 4 weeks prior to first dose of the treatment. 5) Prior treatment with anti-PDL-1/anti-PD-1 or anti-CTL-4 therapy. 6) Known brain metastases, unless these metastases have been treated and stabilized for at least 24 weeks prior to enrolment in the study. Patients with a history of brain metastases must have a head CT with contrast to document stable disease prior to enrolment in the study. 7) Uncontrolled congestive heart failure (NYHA II-IV). 8) Uncontrolled diabetes mellitus as defined by a fasting blood glucose >2 ULN. 9) Any patient receiving treatment with short-acting Octreotide, which cannot be interrupted for 24 h before and 24 h after the administration of 177Lu-DOTATATE , or any patient receiving treatment with Octreotide LAR, which cannot be interrupted for at least 6 weeks before the administration of 177Lu-DOTATATE, unless the tumour uptake observed by Somakit imaging during continued Octreotide treatment is at least as high as normal liver uptake observed by planar imaging. 10) Acute or chronic hepatitis B (e.g., Hepatitis B surface antigen reactive), hepatitis C (e.g., HCV RNA [qualitative] is detected) or known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies). 11) Active, known, or suspected autoimmune disease within the past 2 years. NOTE: Patients with Type I diabetes mellitus, residual hypothyroidism due to autoimmune thyroiditis only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) and Grave’s disease not requiring systemic treatment within the past 2 years are not excluded. 12) Patients with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of start of study treatment. NOTE: Inhaled or topical steroids, and systemic steroid doses > 10 mg daily prednisone equivalent for adrenal replacement are permitted in the absence of active autoimmune disease. 13) Active or prior documented inflammatory bowel disease (e.g., Crohn’s disease, ulcerative colitis). 14) History of allogeneic organ transplant. 15) Known hypersensitivity to nivolumab, 177Lu-DOTATATE or its excipients. 16) Patients with any other significant medical, psychiatric, or surgical condition, currently uncontrolled by treatment, which may interfere with completion of the study. Patients must have recovered from the effects of major surgery or significant traumatic injury at least 14 days before starting treatment. 17) Prior external beam radiation therapy to more than 25% of the bone marrow. 18) Urinary incontinence. 19) Subjects with previous malignancies (except non-melanoma skin canc
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To evaluate the efficacy of 177Lu-DOTATATE plus nivolumab in Grade 3 neuroendocrine tumours or neuroendocrine carcinoma.; Secondary Objective: - To evaluate the efficacy of 177Lu-DOTATATE plus nivolumab in Grade 3 neuroendocrine tumours or neuroendocrine carcinoma by additional measures. - To evaluate impact on survival of 177Lu-DOTATATE plus nivolumab and to evaluate safety of the combination. ;Primary end point(s): Overall Response Rate (ORR) by RECIST v.1.1 at 15 weeks of treatment (+/-1 week).;Timepoint(s) of evaluation of this end point: treatment week 15 | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): • Overall Response Rate (ORR) at 31 weeks of treatment (+/- 1 week). • Overall Response Rate (ORR) by Choi and modified RECIST for immune based therapeutics (iRECIST). • Progression-free Survival (PFS). • Number and Grade of Adverse Events by CTCAE v.5 criteria. • Overall Survival (OS). ; Timepoint(s) of evaluation of this end point: • Treatment week 31 • Through the study | — |
Countries
Spain
Contacts
Public ContactSecretaría
Fundación de investigación de HM Hospitales
Outcome results
None listed